INTUITIVE SURGICAL INC Quarterly Report for Q1 Ended Mar 31, 2019

Summary

Intuitive Surgical Inc. (ISRG) reported a strong first quarter for 2019, demonstrating robust top-line growth and increased procedure volumes. Total revenue rose by 15% year-over-year to $973.7 million, driven by a significant 20% increase in instrument and accessory revenue, fueled by an 18% rise in da Vinci procedures. While system shipments saw a healthy 27% increase, system revenue growth was more moderate at 6%, impacted by a higher proportion of leased systems and lower average selling prices. The company continues to invest heavily in research and development, with R&D expenses increasing by 51%, signaling a commitment to future innovation. Despite a slight decrease in operating income due to increased operating expenses, particularly in R&D and SG&A, the company maintained a strong gross profit margin. The balance sheet remains healthy with substantial cash, cash equivalents, and investments totaling $5.1 billion. The company also saw positive developments with regulatory clearances for new products like the Ion endoluminal system and the da Vinci SP Surgical System, positioning it for future growth. Investors should note the continued strategic expansion into international markets and the ongoing investments in new technologies.

Key Highlights

• 1Total revenue increased 15% to $973.7 million in Q1 2019 compared to Q1 2018.
• 2Da Vinci procedures grew 18% to approximately 282,000 in Q1 2019.
• 3Instrument and accessory revenue increased 20% to $552.3 million.
• 4Systems revenue saw a 6% increase to $247.5 million, with unit shipments up 27%.
• 5Research and Development expenses increased significantly by 51% to $144.0 million, reflecting investment in innovation.
• 6The company's cash, cash equivalents, and investments totaled $5.1 billion as of March 31, 2019.
• 7New product clearances, including the Ion endoluminal system and da Vinci SP Surgical System, indicate future growth potential.

Frequently Asked Questions